Friday, July 10, 2026
🇺🇸 FDA

pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma

Janssen-Cilag International N.V

Janssen-Cilag International N.V.

Janssen-Cilag International N.V clinical programs — 54 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
São Paulo, EU
Employees
13
Programs
161
Drugs
159
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Janssen-Cilag International N.V projects

54 ClinicalTrials.gov programs sponsored by Janssen-Cilag International N.V.

Janssen-Cilag International N.V has 54 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

54 programs

Clinical programs

Page 1 of 2

  1. 42756493BLC1003

    Janssen-Cilag International N.V.

    Localized Bladder Cancer

    phase 1 other active

    1 trial

  2. 63733657EDI1003

    Janssen-Cilag International N.V.

    Alzheimer's Disease (Healthy Participants)

    phase 1 other active

    1 trial

  3. 64007957MMY1008

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  4. 64264681LYM1001

    Janssen-Cilag International N.V.

    non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  5. 64264681LYM1002

    Janssen-Cilag International N.V.

    non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  6. 64407564MMY1002

    Janssen-Cilag International N.V.

    Multiple myeloma

    phase 1 other active

    1 trial

  7. 64407564MMY1004

    Janssen-Cilag International N.V.

    multiple myeloma

    phase 1 other active

    1 trial

  8. 64407564MMY1005

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  9. 64619178EDI1001

    Janssen-Cilag International N.V.

    Previously treated lymphoma (blood cancer) or solid tumors and NHL

    phase 1 other active

    1 trial

  10. 67652000PCR1001

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 1 other active

    1 trial

  11. 67856633LYM1001

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  12. 67856633LYM1002

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  13. 67953964MDD1010

    Janssen-Cilag International N.V.

    Healthy Adult Participants

    phase 1 other active

    1 trial

  14. 67953964MDD1011

    Janssen-Cilag International N.V.

    Healthy Adult Participants.

    phase 1 other active

    1 trial

  15. 70035108EDI1001

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  16. 70218902EDI1001

    Janssen-Cilag International N.V.

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 other active

    1 trial

  17. 73841937NSC1001

    Janssen-Cilag International N.V.

    Advanced Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  18. 74856665AML1001

    Janssen-Cilag International N.V.

    Acute myeloid leukemia or Myelodysplastic syndrome

    phase 1 other active

    1 trial

  19. 75276617ALE1002

    Janssen-Cilag International N.V.

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  20. 77242113PSO1007

    Janssen-Cilag International N.V.

    Renal Impairment

    phase 1 other active

    1 trial

  21. 77242113PSO1008

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  22. 77242113PSO1009

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  23. 77242113PSO1010

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  24. 78278343PCR1001

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer

    phase 1 other active

    1 trial

  25. 78278343PCR1003

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 1 other active

    1 trial

  26. 79635322MMY1002

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 1 other active

    1 trial

  27. 80948543LYM1002

    Janssen-Cilag International N.V.

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies

    phase 1 other active

    1 trial

  28. 87189401PCR1001

    Janssen-Cilag International N.V.

    Advanced Prostate Cancer

    phase 1 other active

    1 trial

  29. 88545223PSO1001

    Janssen-Cilag International N.V.

    Psoriasis

    phase 1 other active

    1 trial

  30. 88549968MPN1001

    Janssen-Cilag International N.V.

    CALR-mutated Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  31. 88998377LYM1001

    Janssen-Cilag International N.V.

    relapsed or refractory B‑cell non-Hodgkin lymphomas

    phase 1 other active

    1 trial

  32. 89853413AML1001

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  33. 89862175LUC1001

    Janssen-Cilag International N.V.

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  34. 90014496LYM1001

    Janssen-Cilag International N.V.

    Non-Hodgkin Lymphoid Malignancies

    phase 1 other active

    1 trial

  35. 90106848EDI1001

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  36. 90189892AML1001

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  37. 90301900HNC1001

    Janssen-Cilag International N.V.

    Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

    phase 1 other active

    1 trial

  38. 95597528EDI1001

    Janssen-Cilag International N.V.

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

  39. A Multi-arm Phase 1b Study of Teclistamab Wit...

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  40. A Phase 1 Study of JNJ-79032421 Targeting Mes... for Advanced Stage Solid Tumors

    Janssen-Cilag International N.V.

    Advanced Stage Solid Tumors

    phase 1 other active

    1 trial

  41. A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  42. A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers

    Janssen-Cilag International N.V.

    Non-Hodgkin Lymphoid Malignancies

    phase 1 other active

    1 trial

  43. A Phase 1 Study of JNJ-87890387 for Advanced Solid Tumors

    Janssen-Cilag International N.V.

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  44. A Phase 1 for Advanced Non-Small Cell Lung Cancer

    Janssen-Cilag International N.V.

    Advanced Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  45. A Phase 1 for Relapsed/refractory B-cell Non…

    Janssen-Cilag International N.V.

    Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

    phase 1 other active

    1 trial

  46. A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors

    Janssen-Cilag International N.V.

    Locally advanced, metastatic NSCLC, CRC, or HNSCC that has recurred or progressed after prior stand of care therapy

    phase 1 other active

    1 trial

  47. A study to assess the effect of single and re... for Plaque Psoriasis

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 1 other active

    1 trial

  48. A study to compare the amount of milvexian in...

    Janssen-Cilag International N.V.

    atherothrombotic and thromboembolic disorders

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Janssen-Cilag International N.V have?

54 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.